AbbVie (ABBV) CFO receives major performance-based stock and option awards
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
AbbVie Inc. executive vice president and chief financial officer Scott T. Reents reported equity awards that increase his direct stake in the company. On February 18, 2026, he acquired an option for 21,937 shares of AbbVie common stock at an exercise price set by the plan, with the option vesting in annual increments of 7,313 shares on February 18, 2027 and 7,312 shares on February 18, 2028 and February 18, 2029. He was also credited with multiple performance-based share and restricted stock unit awards totaling 48,838 shares of common stock, granted in 2023, 2024, and 2025. These awards vested after AbbVie’s Compensation Committee certified the achievement of performance goals tied to earnings per share, relative total shareholder return, and relative return on equity, and the underlying shares are scheduled to be issued to him on February 28, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary
5 transactions reported
Mixed
5 txns
Insider
Reents Scott T
Role
EVP, CHIEF FINANCIAL OFFICER
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Option (Right to buy) | 21,937 | $0.00 | -- |
| Grant/Award | Common Stock, $0.01 par value | 25,062 | $0.00 | -- |
| Grant/Award | Common Stock, $0.01 par value | 8,910 | $0.00 | -- |
| Grant/Award | Common Stock, $0.01 par value | 7,606 | $0.00 | -- |
| Grant/Award | Common Stock, $0.01 par value | 7,260 | $0.00 | -- |
Holdings After Transaction:
Option (Right to buy) — 21,937 shares (Direct);
Common Stock, $0.01 par value — 36,639 shares (Direct)
Footnotes (1)
- Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,313 on February 18, 2027, 7,312 on February 18, 2028, and 7,312 on February 18, 2029.
FAQ
What insider activity did AbbVie (ABBV) report for Scott T. Reents?
AbbVie reported that CFO Scott T. Reents acquired equity awards, including stock options and performance-based share grants, following certification of performance goals by the Compensation Committee. These awards increase his direct interest in AbbVie common stock.
What kind of stock option did AbbVie grant to its CFO?
AbbVie granted an employee stock option for 21,937 shares under the AbbVie Amended and Restated 2013 Incentive Stock Program. The option vests in three annual installments: 7,313 shares in 2027 and 7,312 shares in both 2028 and 2029.
What performance conditions apply to the AbbVie stock awards in this filing?
The reported awards are performance-vesting, linked to earnings per share, relative total shareholder return, and relative return on equity. Vesting occurred after AbbVie’s Compensation Committee certified that these performance goals were attained for the relevant grant periods.
Were these AbbVie insider transactions open-market buys or compensation awards?
All transactions reported are compensation-related awards, not open-market purchases or sales. They include performance-based share and restricted stock unit awards and a stock option grant under AbbVie’s 2013 Incentive Stock Program.